Amgen Inc. buy BMO Capital Markets
Start price
19.12.23
/
50%
€253.60
Target price
19.12.24
€297.31
Performance (%)
-1.16%
End price
20.12.24
€250.65
Summary
This prediction ended on 20.12.24 with a price of €250.65. With a performance of -1.16%, the BUY prediction by BMO_Capital_Markets finished with a loss. BMO_Capital_Markets has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. Dividends of €8.32 are taken into consideration when calculating the performance. BMO_Capital_Markets has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Amgen Inc. | 3.295% | 3.295% | 26.632% |
| iShares Core DAX® | 0.855% | 0.389% | 2.533% |
| iShares Nasdaq 100 | -0.989% | -4.400% | 25.154% |
| iShares Nikkei 225® | -1.781% | -11.216% | 44.398% |
| iShares S&P 500 | 0.057% | 0.778% | 20.953% |
Comments by BMO_Capital_Markets for this prediction
In the thread Amgen Inc. diskutieren
Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $326.00 price target on the stock, up previously from $286.00.
Ratings data for AMGN provided by MarketBeat
In the thread Trading Amgen Inc.
Die von BMO_Capital_Markets gewählte maximale Laufzeit wurde überschritten